• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Ipsen expands presence in US market

Ipsen expands presence in US market

December 16, 2011
CenterWatch Staff

Ipsen's US-based subsidiary, Biomeasure, and its North American Operations group announced that it will further expand its commitment, investment and commercial presence in the US market. Ipsen will make a multi-million dollar capital investment in its Milford, MA research and development and technical operations facility, and will relocate US Operations headquarters from Brisbane, CA, to Bridgewater, NJ, in order to enhance the North American commercial organization.

The existing 77,000 square-foot Milford facility serves as a center for Ipsen's US-based peptide and toxin R&D platforms, as well as a cGMP manufacturing facility focused on production of recombinant proteins for the treatment of hemophilia.

The expansion and renovation capital investment project will deliver a new three-story, 62,000 square-foot building while completely renovating one of the site's two existing buildings. Ground breaking is anticipated for mid-2012, with construction of the new building targeted for completion in early 2014. The new facility will house R&D and process sciences laboratories that support Ipsen's strategic objectives to deliver five New Molecular Entities (NMEs) and three Proofs of Concept (POCs) by 2015.

Ipsen is also moving the headquarters of its US subsidiary to Bridgewater, NJ to a 30,000 square-foot facility, under a six-and-a-half-year lease.

"New Jersey is the leading biopharmaceutical center in the US, and Ipsen is ready and eager to be a part of that community of innovators," said Sean McKercher, president and general manager, Ipsen North America.

The company expects to hire more than 100 employees, including many members of its developing executive team, who will work from the Bridgewater, NJ location. The company expects to begin operation from the Bridgewater location by April 2012.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing